Science1 publisher2 min readPublished
Bird-genome search yields 159 RNA-only tools for inserting genes in human cells
Researchers found 159 R2 retrotransposons in 1,139 avian genomes and engineered variants that reached up to 60% gene insertion in human primary cells. These are RNA-only tools, able to add a gene to the genome without delivering any DNA to the cell.
The Scientist · Science desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- Before engineering, the team mapped which parts of each retrotransposon's protein and untranslated regions are conserved across species and which vary freely.
- The work builds on a 2024 Cell paper that engineered R2 retrotransposons for all-RNA targeted gene integration in mammalian cells, so the concept was already demonstrated.
- A 2025 Nature Biotechnology paper separately used eukaryotic retroelement proteins to insert transgenes into human safe-harbor sites.
- The sequencing data were deposited in the Genome Sequence Archive for Human under accession HRA013312 and opened to the public at publication.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability The 159 variants give engineers many natural scaffolds to screen, so progress no longer rests on improving a single enzyme.
- precedent Because R2 elements differ in where they insert across animal species, a larger catalogue makes extending the range of target sites a plausible next step.
- constraint An integration rate in cultured primary cells does not show how the RNA reaches cells in tissue, how large a gene it will carry, or how often it inserts off target.
The approach is to prospect in nature. Searching across 1,139 avian genomes samples natural variation these enzymes carry, variation that redesigning a single engineered scaffold cannot reach; the team kept the 159 sequences that qualified as R2 elements [1][2]. R2 retrotransposons are mobile genetic elements that copy themselves into one fixed spot in a host genome. The enzyme nicks the target DNA and reverse-transcribes an RNA template directly into the break, the steps structural studies call target-primed reverse transcription [9]. Because the template is RNA, the sequence copied in can be as large as a whole gene, and it lands at a defined target rather than scattering at random [4].
The paper, published in Nature Biotechnology, is a discovery effort. Its stated contribution is to expand the avian R2 resource and to provide additional tools for all-RNA genome editing [10][5].
The 60% deserves a careful read. The abstract reports it as a ceiling, "up to 60%" [4]. It does not give the average across the engineered variants, and it does not say which human primary cells reached that rate or how many of them did [4]. For a tool meant to carry a whole gene to a chosen site, what you need to know is the efficiency you can expect in the cells you plan to treat, and the quoted figure is the best case.
What to watch
- Whether the full paper reports per-variant efficiencies and the specific primary cell types, not just the up-to-60% ceiling.
- Whether any of the 159 variants still work when the RNA is delivered into living tissue rather than added to cultured cells.
- Independent labs retrieving accession HRA013312 to confirm the reported integration rates.